Soluble suppression of tumorigenicity 2 (sST2), but not galactin‐3, adds to prognostication in patients with systemic AL amyloidosis independent of NT‐proBNP and troponin T
暂无分享,去创建一个
A. Jaffe | D. Dingli | A. Dispenzieri | R. Kyle | Shaji K. Kumar | S. Rajkumar | S. Russell | M. Gertz | M. Lacy | A. Saenger | S. Hayman | F. Buadi | S. Zeldenrust | P. Kapoor | N. Leung | R. Go | M. Grogan | L. Hwa